Literature DB >> 28660416

[Botulinum toxin A injections in neuropathic pain : A post-hoc subgroup analysis of patients with peripheral nerve injury].

L Eitner1, J Vollert2, C Maier2, N Attal3.   

Abstract

The randomized controlled trial (RCT) presented in this article showed significant relief in neuropathic pain following subcutaneous injections of botulinum toxin A over 24 weeks compared to placebo. This result was confirmed in a novel post-hoc analysis of the subgroup of 46 patients with peripheral nerve injury. Relevant adverse effects did not occur during the RCT.

Entities:  

Keywords:  Botulinum toxin A; Peripheral neuropathic pain; Risk

Mesh：

Substances：

Year:  2017        PMID： 28660416     DOI： 10.1007/s00482-017-0235-9

Source DB:  PubMed          Journal:  Schmerz        ISSN： 0932-433X            Impact factor:   1.107


  9 in total

1.  Presence of hyperalgesia predicts analgesic efficacy of topically applied capsaicin 8% in patients with peripheral neuropathic pain.

Authors:  T Mainka; N M Malewicz; R Baron; E K Enax-Krumova; R-D Treede; C Maier
Journal:  Eur J Pain       Date:  2015-04-08       Impact factor: 3.931

2.  The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study.

Authors:  Dyveke T Demant; Karen Lund; Jan Vollert; Christoph Maier; Märtha Segerdahl; Nanna B Finnerup; Troels S Jensen; Søren H Sindrup
Journal:  Pain       Date:  2014-08-17       Impact factor: 6.961

3.  Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.

Authors:  R Rolke; R Baron; C Maier; T R Tölle; - D R Treede; A Beyer; A Binder; N Birbaumer; F Birklein; I C Bötefür; S Braune; H Flor; V Huge; R Klug; G B Landwehrmeyer; W Magerl; C Maihöfner; C Rolko; C Schaub; A Scherens; T Sprenger; M Valet; B Wasserka
Journal:  Pain       Date:  2006-05-11       Impact factor: 6.961

4.  Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain.

Authors:  Danièle Ranoux; Nadine Attal; Francoise Morain; D Bouhassira
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

5.  Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial.

Authors:  Nadine Attal; Daniel C de Andrade; Frédéric Adam; Danièle Ranoux; Manoel J Teixeira; Ricardo Galhardoni; Irina Raicher; Nurcan Üçeyler; Claudia Sommer; Didier Bouhassira
Journal:  Lancet Neurol       Date:  2016-03-02       Impact factor: 44.182

6.  Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial.

Authors:  R Y Yuan; J J Sheu; J M Yu; W T Chen; I J Tseng; H H Chang; C J Hu
Journal:  Neurology       Date:  2009-02-25       Impact factor: 9.910

Review 7.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Authors:  Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace
Journal:  Lancet Neurol       Date:  2015-01-07       Impact factor: 44.182

Review 8.  Botulinum Toxin for Neuropathic Pain: A Review of the Literature.

Authors:  Hyun-Mi Oh; Myung Eun Chung
Journal:  Toxins (Basel)       Date:  2015-08-14       Impact factor: 4.546

9.  Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study.

Authors:  C G Maihöfner; M-L S Heskamp
Journal:  Eur J Pain       Date:  2013-10-29       Impact factor: 3.931
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.